<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:podcast="https://podcastindex.org/namespace/1.0" xmlns:media="http://search.yahoo.com/mrss/" version="2.0"><channel><title>CReATe Podcast</title><link>https://www.spreaker.com/podcast/create-podcast--2845933</link><description><![CDATA[CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.]]></description><atom:link href="https://www.spreaker.com/show/2845933/episodes/feed" rel="self" type="application/rss+xml"/><language>en</language><category>Health &amp; Fitness</category><copyright>Copyright CReATe Consortium</copyright><image><url>https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg</url><title>CReATe Podcast</title><link>https://www.spreaker.com/podcast/create-podcast--2845933</link></image><lastBuildDate>Fri, 07 Aug 2026 14:21:18 +0000</lastBuildDate><itunes:author>CReATe Consortium</itunes:author><itunes:owner><itunes:name>CReATe Consortium</itunes:name><itunes:email>feeds@spreaker.com</itunes:email></itunes:owner><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:subtitle>CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.</itunes:subtitle><itunes:summary><![CDATA[CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.]]></itunes:summary><itunes:category text="Health &amp; Fitness"/><itunes:explicit>false</itunes:explicit><itunes:type>episodic</itunes:type><item><title>ALS Untangled Series Ep. 67 - Alpha Lipoic Acid</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-67-alpha-lipoic-acid--73619008</link><description><![CDATA[Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It has several plausible mechanisms for slowing ALS progression. Preclinical studies showed ALA slowed motor function decline. Some patients reported improvement when taking ALA together with other supplements. Here we discuss the mechanism, clinical studies, and potential risks. ]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/73619008</guid><pubDate>Fri, 07 Aug 2026 14:21:12 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/73619008/als_untangled_ep_67_alpha_lipoic_acid_ala.mp3" length="24027008" type="audio/mpeg"/><podcast:transcript url="https://transcription.spreaker.com/starship/d23f5f69-5f13-430a-bcaf-a513b648741f/d23f5f69-5f13-430a-bcaf-a513b648741f.srt" type="application/x-subrip" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/d23f5f69-5f13-430a-bcaf-a513b648741f/d23f5f69-5f13-430a-bcaf-a513b648741f.txt" type="text/plain" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/d23f5f69-5f13-430a-bcaf-a513b648741f/d23f5f69-5f13-430a-bcaf-a513b648741f.vtt" type="text/vtt" language="en"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It has several plausible mechanisms for slowing ALS progression. Preclinical studies showed ALA slowed motor function decline. Some patients reported improvement when taking ALA together...</itunes:subtitle><itunes:summary><![CDATA[Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It has several plausible mechanisms for slowing ALS progression. Preclinical studies showed ALA slowed motor function decline. Some patients reported improvement when taking ALA together with other supplements. Here we discuss the mechanism, clinical studies, and potential risks. ]]></itunes:summary><itunes:duration>601</itunes:duration><itunes:keywords>ala,alphalipoicacid,als,alternativetherapy,caregiver,health,mnd,neurology,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 19 - Dr. Paul Lingor on Fasudil as a Potential Therapeutic for ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-19-dr-paul-lingor-on-fasudil-as-a-potential-therapeutic-for-als--72742807</link><description><![CDATA[Paul Lingor, MD, is Professor for Neurology, Group Leader and Head of the Outpatient Clinics for Motoneuron Disorders and Co-head of the Outpatient Clinics for Movement Disorders and at the Department of Neurology of the TUM Klinikum Rechts der Isar in Munich, Germany.  Here he discusses the recent publication "Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial."<br />]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/72742807</guid><pubDate>Wed, 01 Jul 2026 11:05:08 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/72742807/may_2026_create_authors_pod_ep_18_lingor_rock_als_trial.mp3" length="98827328" type="audio/mpeg"/><podcast:transcript url="https://transcription.spreaker.com/starship/01b4c79a-d7b7-48a3-896f-41c92c63ccc9/01b4c79a-d7b7-48a3-896f-41c92c63ccc9.srt" type="application/x-subrip" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/01b4c79a-d7b7-48a3-896f-41c92c63ccc9/01b4c79a-d7b7-48a3-896f-41c92c63ccc9.txt" type="text/plain" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/01b4c79a-d7b7-48a3-896f-41c92c63ccc9/01b4c79a-d7b7-48a3-896f-41c92c63ccc9.vtt" type="text/vtt" language="en"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Paul Lingor, MD, is Professor for Neurology, Group Leader and Head of the Outpatient Clinics for Motoneuron Disorders and Co-head of the Outpatient Clinics for Movement Disorders and at the Department of Neurology of the TUM Klinikum Rechts der Isar...</itunes:subtitle><itunes:summary><![CDATA[Paul Lingor, MD, is Professor for Neurology, Group Leader and Head of the Outpatient Clinics for Motoneuron Disorders and Co-head of the Outpatient Clinics for Movement Disorders and at the Department of Neurology of the TUM Klinikum Rechts der Isar in Munich, Germany.  Here he discusses the recent publication "Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial."<br />]]></itunes:summary><itunes:duration>2471</itunes:duration><itunes:keywords>als,biomarkers,clinicaltrial,fasudil,health,mnd,munix,neurology,research,rock-inhibition,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 66 - PoNS</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-66-pons--72320854</link><description><![CDATA[Portable Neuromodulation Stimulator (PoNS) is a type of electrical stimulation that can theoretically increase rewiring in the brain (neuroplasticity).  Small trials suggest that it can improve walking in MS but thus far there are no data in people living with ALS.  Here we further discuss the mechanism, studies in other conditions, and potential risks.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/72320854</guid><pubDate>Wed, 03 Jun 2026 14:10:52 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/72320854/als_untangled_series_ep_66_pons.mp3" length="23961728" type="audio/mpeg"/><podcast:transcript url="https://transcription.spreaker.com/starship/5a0a8a07-b1a0-41a4-89d0-31cfe531a21a/5a0a8a07-b1a0-41a4-89d0-31cfe531a21a.srt" type="application/x-subrip" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/5a0a8a07-b1a0-41a4-89d0-31cfe531a21a/5a0a8a07-b1a0-41a4-89d0-31cfe531a21a.txt" type="text/plain" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/5a0a8a07-b1a0-41a4-89d0-31cfe531a21a/5a0a8a07-b1a0-41a4-89d0-31cfe531a21a.vtt" type="text/vtt" language="en"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Portable Neuromodulation Stimulator (PoNS) is a type of electrical stimulation that can theoretically increase rewiring in the brain (neuroplasticity).  Small trials suggest that it can improve walking in MS but thus far there are no data in people...</itunes:subtitle><itunes:summary><![CDATA[Portable Neuromodulation Stimulator (PoNS) is a type of electrical stimulation that can theoretically increase rewiring in the brain (neuroplasticity).  Small trials suggest that it can improve walking in MS but thus far there are no data in people living with ALS.  Here we further discuss the mechanism, studies in other conditions, and potential risks.]]></itunes:summary><itunes:duration>600</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,mnd,neurology,patient,pons,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 65 - ISRIB</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-65-isrib--72021108</link><description><![CDATA[ISRIB stands for “integrated stress response inhibitor).  As we discuss here, it is an oral medication that inhibits an intracellular pathway called the integrative stress response pathway.  It is not FDA approved for any condition but is available in Spain without a prescription.  There are theoretical ways that inhibiting this pathway could help a person with ALS, and there is promising data from preclinical ALS models.  However, it is not clear that ISRIB is soluble enough to get into motor neurons in the brain and spinal cord, and 2 of 3 trials of agents targeting the same pathway failed to show any benefits in people with ALS.  The risks of this product in ALS are not known.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/72021108</guid><pubDate>Fri, 15 May 2026 14:47:51 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/72021108/als_untangled_ep_65_isrib_v2.mp3" length="26284928" type="audio/mpeg"/><podcast:transcript url="https://transcription.spreaker.com/starship/424a0e60-f1bf-4d4f-9f73-d1aa635ffb64/424a0e60-f1bf-4d4f-9f73-d1aa635ffb64.srt" type="application/x-subrip" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/424a0e60-f1bf-4d4f-9f73-d1aa635ffb64/424a0e60-f1bf-4d4f-9f73-d1aa635ffb64.txt" type="text/plain" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/424a0e60-f1bf-4d4f-9f73-d1aa635ffb64/424a0e60-f1bf-4d4f-9f73-d1aa635ffb64.vtt" type="text/vtt" language="en"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>ISRIB stands for “integrated stress response inhibitor).  As we discuss here, it is an oral medication that inhibits an intracellular pathway called the integrative stress response pathway.  It is not FDA approved for any condition but is available in...</itunes:subtitle><itunes:summary><![CDATA[ISRIB stands for “integrated stress response inhibitor).  As we discuss here, it is an oral medication that inhibits an intracellular pathway called the integrative stress response pathway.  It is not FDA approved for any condition but is available in Spain without a prescription.  There are theoretical ways that inhibiting this pathway could help a person with ALS, and there is promising data from preclinical ALS models.  However, it is not clear that ISRIB is soluble enough to get into motor neurons in the brain and spinal cord, and 2 of 3 trials of agents targeting the same pathway failed to show any benefits in people with ALS.  The risks of this product in ALS are not known.]]></itunes:summary><itunes:duration>658</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,isrib,mnd,neurology,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 18 - Dr. Michael Benatar on MMI as a prodromal stage of ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-18-dr-michael-benatar-on-mmi-as-a-prodromal-stage-of-als--71211908</link><description><![CDATA[Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis." ]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/71211908</guid><pubDate>Thu, 09 Apr 2026 14:54:42 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/71211908/mar_2026_create_authors_pod_ep_17_benatar_mmi_non_ai.mp3" length="73388288" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “Proposed Research Criteria for Mild Motor Impairment...</itunes:subtitle><itunes:summary><![CDATA[Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis." ]]></itunes:summary><itunes:duration>1835</itunes:duration><itunes:keywords>als,ftd,health,mmi,mnd,neurology,presymptomatic,prodromal,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 17 - (AI generated) Podcast on C9orf72 Disease Prevention Trials</title><link>https://www.spreaker.com/episode/create-author-series-ep-17-ai-generated-podcast-on-c9orf72-disease-prevention-trials--69355036</link><description><![CDATA[Here we have a podcast produced by artificial intelligence discussing the recent publication “Design considerations for C9orf72 disease prevention trials”. ]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/69355036</guid><pubDate>Thu, 08 Jan 2026 15:13:36 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/69355036/create_author_series_ep_17_artificial_intelligence_generated_podcast_on_c9orf72_disease_prevention_trials.mp3" length="62550848" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Here we have a podcast produced by artificial intelligence discussing the recent publication “Design considerations for C9orf72 disease prevention trials”. </itunes:subtitle><itunes:summary><![CDATA[Here we have a podcast produced by artificial intelligence discussing the recent publication “Design considerations for C9orf72 disease prevention trials”. ]]></itunes:summary><itunes:duration>1564</itunes:duration><itunes:keywords>als,biomarker,c9orf72,ftd,health,mnd,neurology,phenoconversion,pre-symptomatic,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 64 - Wahls Protocol</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-64-wahls-protocol--68979473</link><description><![CDATA[The Wahls Protocol is a diet that may reduce inflammation, oxidative stress, and mitochondrial dysfunction.  Although these are plausible mechanisms for slowing ALS progression, we discuss the fact that there are no actual data to support this hypothesis, and there are risks which are especially important to consider in people living with ALS.  ]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/68979473</guid><pubDate>Wed, 10 Dec 2025 17:47:33 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/68979473/als_untangled_ep_64_wahls_protocol.mp3" length="40120448" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>The Wahls Protocol is a diet that may reduce inflammation, oxidative stress, and mitochondrial dysfunction.  Although these are plausible mechanisms for slowing ALS progression, we discuss the fact that there are no actual data to support this...</itunes:subtitle><itunes:summary><![CDATA[The Wahls Protocol is a diet that may reduce inflammation, oxidative stress, and mitochondrial dysfunction.  Although these are plausible mechanisms for slowing ALS progression, we discuss the fact that there are no actual data to support this hypothesis, and there are risks which are especially important to consider in people living with ALS.  ]]></itunes:summary><itunes:duration>1004</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,mnd,neurology,patient,science,supplement,thewahlsprotocol</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 63 - Psilocybin</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-63-psilocybin--68604876</link><description><![CDATA[Psilocybin is a psychedelic chemical derived from mushrooms.  It is under study for mood problems in people with ALS.  Here we review its plausible mechanisms for slowing ALS progression.  But there are no data from preclinical models, trials or case reports that currently support this benefit.  And there can be serious risks to using this chemical.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/68604876</guid><pubDate>Mon, 17 Nov 2025 16:39:31 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/68604876/als_untangled_ep_63_psilocybin.mp3" length="22789568" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Psilocybin is a psychedelic chemical derived from mushrooms.  It is under study for mood problems in people with ALS.  Here we review its plausible mechanisms for slowing ALS progression.  But there are no data from preclinical models, trials or case...</itunes:subtitle><itunes:summary><![CDATA[Psilocybin is a psychedelic chemical derived from mushrooms.  It is under study for mood problems in people with ALS.  Here we review its plausible mechanisms for slowing ALS progression.  But there are no data from preclinical models, trials or case reports that currently support this benefit.  And there can be serious risks to using this chemical.]]></itunes:summary><itunes:duration>570</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,diet,health,mnd,neurology,patient,psilocybin,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 62 - Ashwagandha</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-62-ashwagandha--68212625</link><description><![CDATA[Here we review ashwagandha a nutritional supplement that has plausible mechanisms for slowing ALS, promising pre-clinical evidence, and a reasonable safety profile.  There is one person with ALS who experienced a reversal of symptoms on a cocktail of treatments that included ashwagandha.  Cases like this are difficult to interpret as there can be multiple explanations for a person experiencing an ALS reversal.  We have not found any other cases suggesting improvement on this product.  We hope to see the data from the completed phase 2 trial soon.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/68212625</guid><pubDate>Mon, 20 Oct 2025 12:00:03 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/68212625/als_untangled_ep_62_ashwagandha.mp3" length="40396928" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Here we review ashwagandha a nutritional supplement that has plausible mechanisms for slowing ALS, promising pre-clinical evidence, and a reasonable safety profile.  There is one person with ALS who experienced a reversal of symptoms on a cocktail of...</itunes:subtitle><itunes:summary><![CDATA[Here we review ashwagandha a nutritional supplement that has plausible mechanisms for slowing ALS, promising pre-clinical evidence, and a reasonable safety profile.  There is one person with ALS who experienced a reversal of symptoms on a cocktail of treatments that included ashwagandha.  Cases like this are difficult to interpret as there can be multiple explanations for a person experiencing an ALS reversal.  We have not found any other cases suggesting improvement on this product.  We hope to see the data from the completed phase 2 trial soon.]]></itunes:summary><itunes:duration>1010</itunes:duration><itunes:keywords>als,alternativetherapy,ashwagandha,caregiver,health,mnd,neurology,patient,science,supplement</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 16 - Dr. Johnathan Cooper-Knock on Exercise and ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-16-dr-johnathan-cooper-knock-on-exercise-and-als--67877239</link><description><![CDATA[Dr. Johnathan Cooper-Knock is a neurologist and clinical lecturer at the University of Sheffield.  His research focuses on genetic causes of ALS.  Here he discusses his recent publication “Extreme exercise in males is linked to mTOR signalling and onset of amyotrophic lateral sclerosis”.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/67877239</guid><pubDate>Wed, 24 Sep 2025 13:13:49 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/67877239/create_author_series_ep_1_dr_jonathon_cooper_knock_on_exercise_and_als.mp3" length="46416128" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Johnathan Cooper-Knock is a neurologist and clinical lecturer at the University of Sheffield.  His research focuses on genetic causes of ALS.  Here he discusses his recent publication “Extreme exercise in males is linked to mTOR signalling and...</itunes:subtitle><itunes:summary><![CDATA[Dr. Johnathan Cooper-Knock is a neurologist and clinical lecturer at the University of Sheffield.  His research focuses on genetic causes of ALS.  Here he discusses his recent publication “Extreme exercise in males is linked to mTOR signalling and onset of amyotrophic lateral sclerosis”.]]></itunes:summary><itunes:duration>1161</itunes:duration><itunes:keywords>als,exercise,gene-environment,health,mnd,mtor,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 61 - Zinc</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-61-zinc--67692061</link><description><![CDATA[Here we review Zinc supplements as a treatment for ALS.  These are inexpensive, reasonably safe at certain doses, and are easy to acquire.  They have plausible mechanisms by which they could slow ALS progression.  However, the data from people living with ALS is not very convincing yet.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/67692061</guid><pubDate>Tue, 09 Sep 2025 16:33:29 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/67692061/als_untangled_series_ep_61_zinc.mp3" length="41358848" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Here we review Zinc supplements as a treatment for ALS.  These are inexpensive, reasonably safe at certain doses, and are easy to acquire.  They have plausible mechanisms by which they could slow ALS progression.  However, the data from people living...</itunes:subtitle><itunes:summary><![CDATA[Here we review Zinc supplements as a treatment for ALS.  These are inexpensive, reasonably safe at certain doses, and are easy to acquire.  They have plausible mechanisms by which they could slow ALS progression.  However, the data from people living with ALS is not very convincing yet.]]></itunes:summary><itunes:duration>1034</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,mnd,neurology,patient,science,supplement,zinc</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 15 - Drs. Terry Heiman-Patterson and Michael Benatar on Clinical Guidance for ALS/FTD at-risk carriers</title><link>https://www.spreaker.com/episode/create-author-series-ep-15-drs-terry-heiman-patterson-and-michael-benatar-on-clinical-guidance-for-als-ftd-at-risk-carriers--66369507</link><description><![CDATA[Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  In this podcast they will be discussing their recent publication “Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD”.<b></b>]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/66369507</guid><pubDate>Mon, 02 Jun 2025 15:54:44 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/66369507/create_author_series_ep_15_drs_terry_heiman_patterson_and_michael_benatar_on_clinical.mp3" length="47320006" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope.  Dr. Michael Benatar is a Professor of Neurology and Chief of the...</itunes:subtitle><itunes:summary><![CDATA[Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  In this podcast they will be discussing their recent publication “Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD”.<b></b>]]></itunes:summary><itunes:duration>1972</itunes:duration><itunes:keywords>als,als/ftd,ftd,health,neurogenetics,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 14 - Drs. Ruben van Eijk and Michael Benatar on Phase 2 Trials and ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-14-drs-ruben-van-eijk-and-michael-benatar-on-phase-2-trials-and-als--65828233</link><description><![CDATA[Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius Center also in Utrecht.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  They will be discussing their recent publication “Rethinking phase 2 trials in amyotrophic lateral sclerosis”.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/65828233</guid><pubDate>Thu, 01 May 2025 16:48:11 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/65828233/mar_2025_create_authors_pod_ep_15_rethinking_clinical_trials.mp3" length="53258953" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius...</itunes:subtitle><itunes:summary><![CDATA[Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius Center also in Utrecht.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  They will be discussing their recent publication “Rethinking phase 2 trials in amyotrophic lateral sclerosis”.]]></itunes:summary><itunes:duration>2219</itunes:duration><itunes:keywords>als,biomarker,clinicaltrials,health,neurology,outcomemeasures,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 13 - Dr. Benatar on Prognostic Markers and ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-13-dr-benatar-on-prognostic-markers-and-als--64437753</link><description><![CDATA[Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  Here he discusses the recent publication “Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis”.<b></b>]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/64437753</guid><pubDate>Tue, 18 Feb 2025 19:59:34 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/64437753/create_author_series_ep_13_dr_benatar_on_prognostic_markers_and_als.mp3" length="38193994" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  Here he discusses the recent publication “Prognostic clinical and biological markers for...</itunes:subtitle><itunes:summary><![CDATA[Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  Here he discusses the recent publication “Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis”.<b></b>]]></itunes:summary><itunes:duration>1591</itunes:duration><itunes:keywords>als,biomarker,clinicaltrials,health,neurofilament,neurology,prognostic,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 12 - Drs. Jesse Crayle and Evadnie Rampersaud on Genetics and ALS Reversal Phenotype</title><link>https://www.spreaker.com/episode/create-author-series-ep-12-drs-jesse-crayle-and-evadnie-rampersaud-on-genetics-and-als-reversal-phenotype--63546472</link><description><![CDATA[Dr. Jesse Crayle is a clinical neuromuscular fellow in the Department of Neurology at Washington University in St. Louis and Dr. Evadnie Rampersaud is a Principal Bioinformatics Research Scientist at St. Jude Children’s Research Hospital.  They will be discussing their publication “Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.”]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/63546472</guid><pubDate>Thu, 02 Jan 2025 16:39:19 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/63546472/create_authors_pod_ep_12_als_reversal_phenotype.mp3" length="63483968" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Jesse Crayle is a clinical neuromuscular fellow in the Department of Neurology at Washington University in St. Louis and Dr. Evadnie Rampersaud is a Principal Bioinformatics Research Scientist at St. Jude Children’s Research Hospital.  They will...</itunes:subtitle><itunes:summary><![CDATA[Dr. Jesse Crayle is a clinical neuromuscular fellow in the Department of Neurology at Washington University in St. Louis and Dr. Evadnie Rampersaud is a Principal Bioinformatics Research Scientist at St. Jude Children’s Research Hospital.  They will be discussing their publication “Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.”]]></itunes:summary><itunes:duration>1588</itunes:duration><itunes:keywords>als,genetics,gwas,health,neurology,phenotype,pma,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 60 - Nuedexta</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-60-nuedexta--63148280</link><description><![CDATA[Nuedexta is a combination of dextromethorphan and quinidine, and is FDA approved for treating “pseudobulbar affect” (a symptom complex where patients lose control of their laughing and crying).  Here we summarize recent trials suggesting that Nuedexta might also help bulbar function (speech, swallowing and oral secretions).  We also discuss important risks, monitoring, and insurance coverage.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/63148280</guid><pubDate>Wed, 04 Dec 2024 19:22:24 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/63148280/als_untangled_series_ep_60_nuedexta.mp3" length="59904128" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Nuedexta is a combination of dextromethorphan and quinidine, and is FDA approved for treating “pseudobulbar affect” (a symptom complex where patients lose control of their laughing and crying).  Here we summarize recent trials suggesting that Nuedexta...</itunes:subtitle><itunes:summary><![CDATA[Nuedexta is a combination of dextromethorphan and quinidine, and is FDA approved for treating “pseudobulbar affect” (a symptom complex where patients lose control of their laughing and crying).  Here we summarize recent trials suggesting that Nuedexta might also help bulbar function (speech, swallowing and oral secretions).  We also discuss important risks, monitoring, and insurance coverage.]]></itunes:summary><itunes:duration>1498</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,dextromethorphan,health,mnd,neurology,nuedexta,patient,pba,pseudobulbaraffect,quinidine,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 59 - Lions Mane</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-59-lions-mane--62610602</link><description><![CDATA[Lions Mane is a mushroom that has neuroprotective, neurotrophic, antioxidant, and anti-inflammatory properties.  Here we review what is known about its use in ALS models as well as patients living with the disease.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/62610602</guid><pubDate>Mon, 04 Nov 2024 17:35:25 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/62610602/als_untangled_series_ep_59_lions_mane.mp3" length="41211008" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Lions Mane is a mushroom that has neuroprotective, neurotrophic, antioxidant, and anti-inflammatory properties.  Here we review what is known about its use in ALS models as well as patients living with the disease.</itunes:subtitle><itunes:summary><![CDATA[Lions Mane is a mushroom that has neuroprotective, neurotrophic, antioxidant, and anti-inflammatory properties.  Here we review what is known about its use in ALS models as well as patients living with the disease.]]></itunes:summary><itunes:duration>1031</itunes:duration><itunes:keywords>als,alternativetherapy,antiinflammatory,antioxidant,caregiver,health,lionsmane,mnd,neurology,neuroprotective,neurotrophic,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 58 - Insulin</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-58-insulin--62179132</link><description><![CDATA[Insulin is a hormone most commonly used to lower blood sugar in people with diabetes.  Here we talk about some theoretical ways it might help help people with ALS, as well as the lack of convincing case reports or trials and the risks.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/62179132</guid><pubDate>Tue, 01 Oct 2024 13:42:10 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/62179132/als_untangled_series_ep_58_insulin.mp3" length="46839488" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Insulin is a hormone most commonly used to lower blood sugar in people with diabetes.  Here we talk about some theoretical ways it might help help people with ALS, as well as the lack of convincing case reports or trials and the risks.</itunes:subtitle><itunes:summary><![CDATA[Insulin is a hormone most commonly used to lower blood sugar in people with diabetes.  Here we talk about some theoretical ways it might help help people with ALS, as well as the lack of convincing case reports or trials and the risks.]]></itunes:summary><itunes:duration>1171</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,insulin,mnd,neurology,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 57 - Caffeine</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-57-caffeine--61274097</link><description><![CDATA[Caffeine is a chemical most of us ingest every day.  In addition to its stimulant properties, there are some theoretical ways it could help slow ALS progression.  Here we discuss the contradictory pre-clinical models and the lack of a convincing relationship between caffeine intake and ALS progression in natural history studies.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/61274097</guid><pubDate>Thu, 05 Sep 2024 15:02:11 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/61274097/als_untangled_series_ep_57_caffeine.mp3" length="52112768" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Caffeine is a chemical most of us ingest every day.  In addition to its stimulant properties, there are some theoretical ways it could help slow ALS progression.  Here we discuss the contradictory pre-clinical models and the lack of a convincing...</itunes:subtitle><itunes:summary><![CDATA[Caffeine is a chemical most of us ingest every day.  In addition to its stimulant properties, there are some theoretical ways it could help slow ALS progression.  Here we discuss the contradictory pre-clinical models and the lack of a convincing relationship between caffeine intake and ALS progression in natural history studies.]]></itunes:summary><itunes:duration>1303</itunes:duration><itunes:keywords>als,alternativetherapy,caffeine,caregiver,health,mnd,neurology,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 11 - Dr. Benatar and the Miami Framework for ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-11-dr-benatar-and-the-miami-framework-for-als--61012788</link><description><![CDATA[Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology”. ]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/61012788</guid><pubDate>Tue, 13 Aug 2024 12:13:30 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/61012788/create_author_series_ep_11_dr_benatar_and_the_miami_framework_for_als.mp3" length="72254528" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “The Miami Framework for ALS and related...</itunes:subtitle><itunes:summary><![CDATA[Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology”. ]]></itunes:summary><itunes:duration>1807</itunes:duration><itunes:keywords>als,biomarkers,frontotemporaldementia,ftd,health,neurology,phenotype,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 10 - Drs. McHutchison and Benatar on Cognitive and Behavioral Changes in MND</title><link>https://www.spreaker.com/episode/create-author-series-ep-10-drs-mchutchison-and-benatar-on-cognitive-and-behavioral-changes-in-mnd--58695999</link><description><![CDATA[Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Temporal course of cognitive and behavioural changes in motor neuron diseases”.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/58695999</guid><pubDate>Thu, 15 Feb 2024 15:14:43 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/58695999/create_author_series_ep_10_drs_mchutchison_and_benatar_on_cognitive_changes_in_als_1.mp3" length="71632448" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at...</itunes:subtitle><itunes:summary><![CDATA[Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Temporal course of cognitive and behavioural changes in motor neuron diseases”.]]></itunes:summary><itunes:duration>1791</itunes:duration><itunes:keywords>als,c9orf,cognition,ftd,health,mnd,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 9 - Drs. Heatwole and Benatar on Patient Reported Outcome Measures and ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-9-drs-heatwole-and-benatar-on-patient-reported-outcome-measures-and-als--58187612</link><description><![CDATA[Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure” and its role as a patient reported outcome measure for ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/58187612</guid><pubDate>Wed, 03 Jan 2024 16:42:23 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/58187612/create_author_series_ep_9_drs_heatwole_and_benatar_on_patient_reported_outcome_measures_and_als.mp3" length="86463488" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and...</itunes:subtitle><itunes:summary><![CDATA[Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure” and its role as a patient reported outcome measure for ALS.]]></itunes:summary><itunes:duration>2162</itunes:duration><itunes:keywords>als,als-hi,diseaseburden,health,neurology,patientreportedoutcome,pro,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 56 - Sodium Chlorite</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-56-sodium-chlorite--57649249</link><description><![CDATA[Sodium chlorite is an experimental drug targeting macrophage activation.  It exists in different formulations.  An oral formulation has potentially deadly side effects.  An IV formulation called NP001 has been in recent trials targeting a subset of people with ALS.  Here we review the interesting development of this product and where we expect that to go in the near future.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/57649249</guid><pubDate>Wed, 15 Nov 2023 15:32:25 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/57649249/als_untangled_series_ep_56_sodium_chlorite.mp3" length="53362688" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Sodium chlorite is an experimental drug targeting macrophage activation.  It exists in different formulations.  An oral formulation has potentially deadly side effects.  An IV formulation called NP001 has been in recent trials targeting a subset of...</itunes:subtitle><itunes:summary><![CDATA[Sodium chlorite is an experimental drug targeting macrophage activation.  It exists in different formulations.  An oral formulation has potentially deadly side effects.  An IV formulation called NP001 has been in recent trials targeting a subset of people with ALS.  Here we review the interesting development of this product and where we expect that to go in the near future.]]></itunes:summary><itunes:duration>1335</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,mnd,neurology,np001,patient,science,sodiumchlorite</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 55 - Rituximab</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-55-rituximab--57169626</link><description><![CDATA[Rituximab is an intravenous product that reduces B lymphocytes.  It can help improve strength in patients with myasthenia gravis and multi-focal motor neuropathy, neuromuscular diseases that are caused by circulating antibodies made by B lymphocytes.  In this podcast we examine the possible use of rituximab to treat patients with ALS]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/57169626</guid><pubDate>Mon, 09 Oct 2023 18:15:54 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/57169626/als_untangled_series_ep_55_rituximab.mp3" length="30292928" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Rituximab is an intravenous product that reduces B lymphocytes.  It can help improve strength in patients with myasthenia gravis and multi-focal motor neuropathy, neuromuscular diseases that are caused by circulating antibodies made by B lymphocytes....</itunes:subtitle><itunes:summary><![CDATA[Rituximab is an intravenous product that reduces B lymphocytes.  It can help improve strength in patients with myasthenia gravis and multi-focal motor neuropathy, neuromuscular diseases that are caused by circulating antibodies made by B lymphocytes.  In this podcast we examine the possible use of rituximab to treat patients with ALS]]></itunes:summary><itunes:duration>758</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,mnd,neurology,patient,rituximab,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 54 - Ozone Therapy</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-54-ozone-therapy--56700733</link><description><![CDATA[Ozone is an oxidizing agent which has some surprisingly plausible mechanisms by which it could influence ALS progression.  It can also be dangerous.  The FDA has warned against using it as a treatment for any disease.  Further studies are needed to determine whether there is any  dose or route of administration that might be safe and effective for use in people with ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/56700733</guid><pubDate>Tue, 05 Sep 2023 15:51:41 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/56700733/create_podcast_54_ozone_therapy.mp3" length="44955968" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Ozone is an oxidizing agent which has some surprisingly plausible mechanisms by which it could influence ALS progression.  It can also be dangerous.  The FDA has warned against using it as a treatment for any disease.  Further studies are needed to...</itunes:subtitle><itunes:summary><![CDATA[Ozone is an oxidizing agent which has some surprisingly plausible mechanisms by which it could influence ALS progression.  It can also be dangerous.  The FDA has warned against using it as a treatment for any disease.  Further studies are needed to determine whether there is any  dose or route of administration that might be safe and effective for use in people with ALS.]]></itunes:summary><itunes:duration>1124</itunes:duration><itunes:keywords>als,alternativetherapy,caregiver,health,mnd,neurology,ozone,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 53 - Astaxanthin</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-53-astaxanthin--56405100</link><description><![CDATA[Astaxanthin is a naturally occurring chemical which has plausible mechanisms for treating ALS and appears reasonably safe and well tolerated in non-ALS trials.  We look forward to ALS-specific trials planned later this year which should shed important light on whether this is specifically safe for people with ALS, and whether it really can slow ALS progression.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/56405100</guid><pubDate>Tue, 08 Aug 2023 15:52:14 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/56405100/als_untangled_series_ep_53_astaxanthin.mp3" length="49648448" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Astaxanthin is a naturally occurring chemical which has plausible mechanisms for treating ALS and appears reasonably safe and well tolerated in non-ALS trials.  We look forward to ALS-specific trials planned later this year which should shed important...</itunes:subtitle><itunes:summary><![CDATA[Astaxanthin is a naturally occurring chemical which has plausible mechanisms for treating ALS and appears reasonably safe and well tolerated in non-ALS trials.  We look forward to ALS-specific trials planned later this year which should shed important light on whether this is specifically safe for people with ALS, and whether it really can slow ALS progression.]]></itunes:summary><itunes:duration>1242</itunes:duration><itunes:keywords>als,alternativetherapy,astaxanthin,caregiver,health,mnd,neurodegeneration,neurology,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 8 Part I - Drs. Turner and Benatar on Neurofilament Light Chain as Biomarker for ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-8-part-i-drs-turner-and-benatar-on-neurofilament-light-chain-as-biomarker-for-als--54290354</link><description><![CDATA[Dr. Martin Turner is a Professor of Clinical Neurology &amp; Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal”, and the potential role of NfL as a biomarker for ALS. This is part I of a two part series.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/54290354</guid><pubDate>Mon, 12 Jun 2023 12:49:15 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/54290354/create_author_series_ep_8_part_i_drs_turner_and_benatar_on_neurofilament_light_chain_as_biomarker_for_als.mp3" length="49256768" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Martin Turner is a Professor of Clinical Neurology &amp;amp; Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the...</itunes:subtitle><itunes:summary><![CDATA[Dr. Martin Turner is a Professor of Clinical Neurology &amp; Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal”, and the potential role of NfL as a biomarker for ALS. This is part I of a two part series.]]></itunes:summary><itunes:duration>1232</itunes:duration><itunes:keywords>als,biomarker,health,neurofilamentlightchain,neurology,nfl,research,science,therapy</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series Ep. 8 Part II - Drs. Turner and Benatar on Neurofilament Light Chain as Biomarker for ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-8-part-ii-drs-turner-and-benatar-on-neurofilament-light-chain-as-biomarker-for-als--54290758</link><description><![CDATA[Dr. Martin Turner is a Professor of Clinical Neurology &amp; Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal”, and the potential role of NfL as a biomarker for ALS. This is part II of a two part series.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/54290758</guid><pubDate>Mon, 12 Jun 2023 12:49:08 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/54290758/create_author_series_ep_8_part_ii_drs_turner_and_benatar_on_neurofilament_light_chain_as_biomarker_for_als.mp3" length="61139648" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Martin Turner is a Professor of Clinical Neurology &amp;amp; Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the...</itunes:subtitle><itunes:summary><![CDATA[Dr. Martin Turner is a Professor of Clinical Neurology &amp; Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal”, and the potential role of NfL as a biomarker for ALS. This is part II of a two part series.]]></itunes:summary><itunes:duration>1529</itunes:duration><itunes:keywords>als,biomarker,health,neurofilamentlightchain,neurology,nfl,research,science,therapy</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 52 - Antimycobacterial Antibiotics</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-52-antimycobacterial-antibiotics--53707118</link><description><![CDATA[There is a theorized association between mycobacteria and ALS, and two published case reports described improvements in ALS-like conditions (both with atypical features) after treatment with antimycobacterial antibiotics. Here we review these in detail and discuss our thoughts on how they might change our approach in certain patients in the future.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/53707118</guid><pubDate>Mon, 01 May 2023 16:32:37 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/53707118/als_untangled_series_ep_52_antimycobacterial_antibiotics.mp3" length="40243328" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>There is a theorized association between mycobacteria and ALS, and two published case reports described improvements in ALS-like conditions (both with atypical features) after treatment with antimycobacterial antibiotics. Here we review these in...</itunes:subtitle><itunes:summary><![CDATA[There is a theorized association between mycobacteria and ALS, and two published case reports described improvements in ALS-like conditions (both with atypical features) after treatment with antimycobacterial antibiotics. Here we review these in detail and discuss our thoughts on how they might change our approach in certain patients in the future.]]></itunes:summary><itunes:duration>1007</itunes:duration><itunes:keywords>als,antimycobacteria,caregiver,health,mnd,mycobacterium,neurology,paratuberculosis,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 51 - Corticosteroids</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-51-corticosteroids--53429573</link><description><![CDATA[Corticosteroids are a class of medications with well-studied effects on the immune system and some people living with ALS have reported benefits from them online.  Here we review the pre-clinical and clinical data.  We conclude that there is currently no clear evidence that steroids can slow ALS progression, and they can have many side effects.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/53429573</guid><pubDate>Mon, 03 Apr 2023 15:24:16 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/53429573/als_untangled_series_ep_51_corticosteroids.mp3" length="32737088" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Corticosteroids are a class of medications with well-studied effects on the immune system and some people living with ALS have reported benefits from them online.  Here we review the pre-clinical and clinical data.  We conclude that there is currently...</itunes:subtitle><itunes:summary><![CDATA[Corticosteroids are a class of medications with well-studied effects on the immune system and some people living with ALS have reported benefits from them online.  Here we review the pre-clinical and clinical data.  We conclude that there is currently no clear evidence that steroids can slow ALS progression, and they can have many side effects.]]></itunes:summary><itunes:duration>819</itunes:duration><itunes:keywords>als,caregiver,corticosteroids,glucocorticoids,health,mnd,neurology,patient,science,steroids</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 50 - Butyrate</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-50-butyrate--53074864</link><description><![CDATA[Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/53074864</guid><pubDate>Thu, 02 Mar 2023 18:35:23 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/53074864/als_untangled_series_ep_50_butyrate.mp3" length="62395328" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong...</itunes:subtitle><itunes:summary><![CDATA[Butyrates have plausible mechanisms for slowing ALS progression and positive pre-clinical studies. One trial suggests that sodium phenylbutyrate (NaPB) in combination with Tauroursodeoxycholic acid (TUDCA) can slow ALS progression and prolong survival, but the specific contribution of NaPB toward this effect is unclear. Butyrates appear reasonably safe for use in humans. Based on the above information, we support a trial of a butyrate in PALS, but we cannot yet recommend one as a treatment.]]></itunes:summary><itunes:duration>1560</itunes:duration><itunes:keywords>als,butyrates,caregiver,health,mnd,napb,neurology,patient,science,sodiumphenylbutyrate,tauroursodeoxycholid,tudca</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 49 - Methylcobalamin</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-49-methylcobalamin--52670714</link><description><![CDATA[Methylcobalamin is a specific precursor to B12 (cobalamin).  It has promising mechanisms by which it could slow ALS progression.  Two trials done in Japan suggest that 50mg via intramuscular injection twice weekly can slow ALS progression and prolong survival. Here we discuss the evidence for ultra-high dose methylcobalamin in patients with ALS and conclude that it may offer benefit, but only if administered within the first year of symptoms.  If started after the first year, there is no evidence of benefit.  It appears reasonably safe.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/52670714</guid><pubDate>Wed, 08 Feb 2023 14:35:37 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/52670714/create_podcasts_ep_49_methylcobalamin.mp3" length="64209728" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Methylcobalamin is a specific precursor to B12 (cobalamin).  It has promising mechanisms by which it could slow ALS progression.  Two trials done in Japan suggest that 50mg via intramuscular injection twice weekly can slow ALS progression and prolong...</itunes:subtitle><itunes:summary><![CDATA[Methylcobalamin is a specific precursor to B12 (cobalamin).  It has promising mechanisms by which it could slow ALS progression.  Two trials done in Japan suggest that 50mg via intramuscular injection twice weekly can slow ALS progression and prolong survival. Here we discuss the evidence for ultra-high dose methylcobalamin in patients with ALS and conclude that it may offer benefit, but only if administered within the first year of symptoms.  If started after the first year, there is no evidence of benefit.  It appears reasonably safe.]]></itunes:summary><itunes:duration>1606</itunes:duration><itunes:keywords>als,b12,caregiver,health,methylcobalamin,mnd,neurology,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series: Ep. 7 - Drs. Jim Caress and Michael Benatar on Electronic Health Records and ALS research</title><link>https://www.spreaker.com/episode/create-author-series-ep-7-drs-jim-caress-and-michael-benatar-on-electronic-health-records-and-als-research--52361987</link><description><![CDATA[Dr. Jim Caress is a Professor of Neurology at Wake Forest University and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication titled “Harnessing the power of the electronic health record for ALS research and quality improvement: CReATe CAPTURE-ALS and the ALS Toolkit”.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/52361987</guid><pubDate>Thu, 05 Jan 2023 15:46:28 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/52361987/create_author_series_ep_7_drs_jim_caress_and_michael_benatar_on_electronic_health_records_and_als_research.mp3" length="88327808" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Jim Caress is a Professor of Neurology at Wake Forest University and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be...</itunes:subtitle><itunes:summary><![CDATA[Dr. Jim Caress is a Professor of Neurology at Wake Forest University and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication titled “Harnessing the power of the electronic health record for ALS research and quality improvement: CReATe CAPTURE-ALS and the ALS Toolkit”.]]></itunes:summary><itunes:duration>2209</itunes:duration><itunes:keywords>als,clinic,ehr,health,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series: Ep. 6 - Drs. Mary-Louise Rogers and Michael Benatar on Urine Biomarkers for ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-6-drs-mary-louise-rogers-and-michael-benatar-on-urine-biomarkers-for-als--51161441</link><description><![CDATA[Dr. Mary-Louise Rogers is an Associate Professor at the College of Medicine and Public Health at Flinders University and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  They will be discussing their recent publication titled “Urinary neopterin:  A novel biomarker of disease progression in amyotrophic lateral sclerosis,” which discusses the importance of biomarkers in ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/51161441</guid><pubDate>Wed, 07 Sep 2022 12:38:52 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/51161441/create_author_series_ep_6_drs_mary_louise_rogers_and_michael_benatar_and_urine_biomarkers_for_als.mp3" length="68713076" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Mary-Louise Rogers is an Associate Professor at the College of Medicine and Public Health at Flinders University and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center...</itunes:subtitle><itunes:summary><![CDATA[Dr. Mary-Louise Rogers is an Associate Professor at the College of Medicine and Public Health at Flinders University and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  They will be discussing their recent publication titled “Urinary neopterin:  A novel biomarker of disease progression in amyotrophic lateral sclerosis,” which discusses the importance of biomarkers in ALS.]]></itunes:summary><itunes:duration>1720</itunes:duration><itunes:keywords>als,biomarker,health,neopterin,neurology,pharmacodynamic,proinflammatory,research,science,urine</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series: Ep. 5 - Dr. Marc Weisskopf and Environmental Risk Factors in ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-5-dr-marc-weisskopf-and-environmental-risk-factors-in-als--50943006</link><description><![CDATA[Dr. Marc Weisskopf is the Cecil K. and Philip Drinker Professor of Environmental Epidemiology and Physiology at Harvard T. H. Chan School of Public Health.  In this interview, he discusses his recent publication titled “Occupational lead exposure and survival with amyotrophic lateral sclerosis,” which discusses the role that environmental risk factors could play in ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/50943006</guid><pubDate>Wed, 17 Aug 2022 18:55:11 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/50943006/create_author_series_ep_6_weisskopf.mp3" length="78256280" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Marc Weisskopf is the Cecil K. and Philip Drinker Professor of Environmental Epidemiology and Physiology at Harvard T. H. Chan School of Public Health.  In this interview, he discusses his recent publication titled “Occupational lead exposure and...</itunes:subtitle><itunes:summary><![CDATA[Dr. Marc Weisskopf is the Cecil K. and Philip Drinker Professor of Environmental Epidemiology and Physiology at Harvard T. H. Chan School of Public Health.  In this interview, he discusses his recent publication titled “Occupational lead exposure and survival with amyotrophic lateral sclerosis,” which discusses the role that environmental risk factors could play in ALS.]]></itunes:summary><itunes:duration>1959</itunes:duration><itunes:keywords>als,biomarkers,epidemiology,health,job-exposure,lead,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series: Ep. 4 - Drs. Melissa Nel and Jeannine Heckmann and African Genetic Diversity in ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-4-drs-melissa-nel-and-jeannine-heckmann-and-african-genetic-diversity-in-als--50437083</link><description><![CDATA[Dr. Melissa Nel is a Research Fellow, and Dr. Jeannine Heckmann a Professor of Neurology, both at the University of Cape Town in South Africa.  In this interview, they discuss their recent publication titled “Revealing the Mutational Spectrum in South Africans with Amyotrophic Lateral Sclerosis” which highlights that ALS patients of African genetic ancestry should be included in large-scale ALS gene discovery efforts.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/50437083</guid><pubDate>Fri, 01 Jul 2022 17:23:58 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/50437083/create_author_series_nel_heckmann.mp3" length="58873376" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Melissa Nel is a Research Fellow, and Dr. Jeannine Heckmann a Professor of Neurology, both at the University of Cape Town in South Africa.  In this interview, they discuss their recent publication titled “Revealing the Mutational Spectrum in South...</itunes:subtitle><itunes:summary><![CDATA[Dr. Melissa Nel is a Research Fellow, and Dr. Jeannine Heckmann a Professor of Neurology, both at the University of Cape Town in South Africa.  In this interview, they discuss their recent publication titled “Revealing the Mutational Spectrum in South Africans with Amyotrophic Lateral Sclerosis” which highlights that ALS patients of African genetic ancestry should be included in large-scale ALS gene discovery efforts.]]></itunes:summary><itunes:duration>1474</itunes:duration><itunes:keywords>africans,als,gene-discovery,genetics,health,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 48 - Vitamin C</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-48-vitamin-c--50026471</link><description><![CDATA[Vitamin C is a very popular supplement in people living with ALS, perhaps due to its antioxidant mechanism, low cost, and low risk.  Here we review the data on Vitamin C in ALS in hopes of helping patients make more informed decisions about it.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/50026471</guid><pubDate>Wed, 01 Jun 2022 15:03:09 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/50026471/als_untangled_series_ep_48_vitamin_c.mp3" length="29782208" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Vitamin C is a very popular supplement in people living with ALS, perhaps due to its antioxidant mechanism, low cost, and low risk.  Here we review the data on Vitamin C in ALS in hopes of helping patients make more informed decisions about it.</itunes:subtitle><itunes:summary><![CDATA[Vitamin C is a very popular supplement in people living with ALS, perhaps due to its antioxidant mechanism, low cost, and low risk.  Here we review the data on Vitamin C in ALS in hopes of helping patients make more informed decisions about it.]]></itunes:summary><itunes:duration>745</itunes:duration><itunes:keywords>als,caregiver,health,mnd,neurology,patient,science,supplement,vitaminc</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 47 - Melatonin</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-47-melatonin--49642251</link><description><![CDATA[Melatonin is a naturally occurring hormone, and it is commonly taken as a supplement to induce sleep.  Here we review some surprising mechanisms, pre-clinical data and case reports supporting its potential as an ALS treatment.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/49642251</guid><pubDate>Tue, 03 May 2022 14:52:44 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/49642251/create_podcast_47.mp3" length="43238528" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Melatonin is a naturally occurring hormone, and it is commonly taken as a supplement to induce sleep.  Here we review some surprising mechanisms, pre-clinical data and case reports supporting its potential as an ALS treatment.</itunes:subtitle><itunes:summary><![CDATA[Melatonin is a naturally occurring hormone, and it is commonly taken as a supplement to induce sleep.  Here we review some surprising mechanisms, pre-clinical data and case reports supporting its potential as an ALS treatment.]]></itunes:summary><itunes:duration>1081</itunes:duration><itunes:keywords>als,caregiver,health,melatonin,mnd,neurology,patient,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series Ep. 46 - Light Therapy</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-46-light-therapy--49284105</link><description><![CDATA[Light therapy has surprisingly plausible mechanisms through which it could influence the progression of ALS.  Here we describe these, as well as some limited pre-clinical and clinical data, and information about dosing, risks, and costs.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/49284105</guid><pubDate>Fri, 01 Apr 2022 16:47:23 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/49284105/als_untangled_series_ep_46_light_therapy.mp3" length="41445248" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Light therapy has surprisingly plausible mechanisms through which it could influence the progression of ALS.  Here we describe these, as well as some limited pre-clinical and clinical data, and information about dosing, risks, and costs.</itunes:subtitle><itunes:summary><![CDATA[Light therapy has surprisingly plausible mechanisms through which it could influence the progression of ALS.  Here we describe these, as well as some limited pre-clinical and clinical data, and information about dosing, risks, and costs.]]></itunes:summary><itunes:duration>1037</itunes:duration><itunes:keywords>als,caregiver,health,mnd,neurology,patient,science,transcutaneous,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 45 - Ketogenic Diets</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-45-ketogenic-diets--48935020</link><description><![CDATA[Ketogenic diets, resulting in the formation of ketone bodies, have long been used to promote weight loss and to treat refractory epilepsy.  Here we summarize the available data on ketogenic diets as a treatment for ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/48935020</guid><pubDate>Thu, 03 Mar 2022 13:46:31 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/48935020/als_untangled_series_ep_45_ketogenic_diets.mp3" length="39885248" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Ketogenic diets, resulting in the formation of ketone bodies, have long been used to promote weight loss and to treat refractory epilepsy.  Here we summarize the available data on ketogenic diets as a treatment for ALS.</itunes:subtitle><itunes:summary><![CDATA[Ketogenic diets, resulting in the formation of ketone bodies, have long been used to promote weight loss and to treat refractory epilepsy.  Here we summarize the available data on ketogenic diets as a treatment for ALS.]]></itunes:summary><itunes:duration>998</itunes:duration><itunes:keywords>als,caregiver,health,ketogenic,mnd,neurology,patient,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series: Ep. 3 - Dr. Michael Benatar and Neurofilament Biomarkers for ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-3-dr-michael-benatar-and-neurofilament-biomarkers-for-als--48025467</link><description><![CDATA[Dr. Michael Benatar is the Walter Bradley Chair in ALS Research, a Professor of Neurology at the University of Miami Miller School of Medicine and the Principal Investigator of the CReATe Consortium. In this interview, he will discuss the CReATe Consortium’s recent paper titled "Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS". The interview highlights the specific ways in which validated biomarkers could benefit therapeutic development for ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/48025467</guid><pubDate>Wed, 22 Dec 2021 16:03:29 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/48025467/sep_2021_create_authors_podcast_benatar.mp3" length="87610520" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Michael Benatar is the Walter Bradley Chair in ALS Research, a Professor of Neurology at the University of Miami Miller School of Medicine and the Principal Investigator of the CReATe Consortium. In this interview, he will discuss the CReATe...</itunes:subtitle><itunes:summary><![CDATA[Dr. Michael Benatar is the Walter Bradley Chair in ALS Research, a Professor of Neurology at the University of Miami Miller School of Medicine and the Principal Investigator of the CReATe Consortium. In this interview, he will discuss the CReATe Consortium’s recent paper titled "Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS". The interview highlights the specific ways in which validated biomarkers could benefit therapeutic development for ALS.]]></itunes:summary><itunes:duration>2193</itunes:duration><itunes:keywords>als,biomarker,health,neurofilament,neurology,pharmacodynamic,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series: Ep. 2 - Dr. Corey McMillan and Cognition in ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-2-dr-corey-mcmillan-and-cognition-in-als--47312631</link><description><![CDATA[Dr. Corey McMillan is an Associate Professor of Neurology at the University of Pennsylvania and this interview will be discussing his recent paper titled “Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis (ALS)” which discusses the contribution of genetics to heterogeneity we observe in ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/47312631</guid><pubDate>Fri, 05 Nov 2021 12:45:19 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/47312631/sep_2021_create_authors_podcast_mcmillan.mp3" length="71690564" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Corey McMillan is an Associate Professor of Neurology at the University of Pennsylvania and this interview will be discussing his recent paper titled “Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral...</itunes:subtitle><itunes:summary><![CDATA[Dr. Corey McMillan is an Associate Professor of Neurology at the University of Pennsylvania and this interview will be discussing his recent paper titled “Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis (ALS)” which discusses the contribution of genetics to heterogeneity we observe in ALS.]]></itunes:summary><itunes:duration>1794</itunes:duration><itunes:keywords>als,cognition,ftd,health,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>CReATe Author Series: Ep. 1 - Dr. Benjamin Murdock and Immune Mechanisms in ALS</title><link>https://www.spreaker.com/episode/create-author-series-ep-1-dr-benjamin-murdock-and-immune-mechanisms-in-als--46817908</link><description><![CDATA[Dr. Benjamin Murdock is a Research Assistant Professor of Neurology at the University of Michigan and this interview will be discussing his recent paper titled “NK Cells associated with ALS in a sex- and age-dependent manner” which further expands his ongoing research examining the impact of sex and age on immune mechanisms in ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/46817908</guid><pubDate>Mon, 04 Oct 2021 17:48:18 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/46817908/sep_2021_create_authors_podcast_murdock_2.mp3" length="57888884" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Dr. Benjamin Murdock is a Research Assistant Professor of Neurology at the University of Michigan and this interview will be discussing his recent paper titled “NK Cells associated with ALS in a sex- and age-dependent manner” which further expands his...</itunes:subtitle><itunes:summary><![CDATA[Dr. Benjamin Murdock is a Research Assistant Professor of Neurology at the University of Michigan and this interview will be discussing his recent paper titled “NK Cells associated with ALS in a sex- and age-dependent manner” which further expands his ongoing research examining the impact of sex and age on immune mechanisms in ALS.]]></itunes:summary><itunes:duration>1449</itunes:duration><itunes:keywords>als,health,immunotherapy,neurology,research,science</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 44 - Tamoxifen</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-44-tamoxifen--44870641</link><description><![CDATA[Tamoxifen is an FDA approved estrogen receptor modulator that is currently prescribed to treat breast cancer.  Here we review surprising evidence that it could someday be an ALS treatment, including its mechanisms of action, pre-clinical data, cases, trials and risks.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/44870641</guid><pubDate>Tue, 06 Jul 2021 20:06:39 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/44870641/create_podcast_44.mp3" length="41088836" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Tamoxifen is an FDA approved estrogen receptor modulator that is currently prescribed to treat breast cancer.  Here we review surprising evidence that it could someday be an ALS treatment, including its mechanisms of action, pre-clinical data, cases,...</itunes:subtitle><itunes:summary><![CDATA[Tamoxifen is an FDA approved estrogen receptor modulator that is currently prescribed to treat breast cancer.  Here we review surprising evidence that it could someday be an ALS treatment, including its mechanisms of action, pre-clinical data, cases, trials and risks.]]></itunes:summary><itunes:duration>1028</itunes:duration><itunes:keywords>als,caregiver,health,mnd,neurology,patient,science,supplement,tamoxifen,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 43 - Spirulina (blue green algae)</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-43-spirulina-blue-green-algae--44870637</link><description><![CDATA[Spirulina, or blue green algae, is a supplement that is claimed to have antioxidant and anti-inflammatory properties.  Here we review the problems we found with the single relevant preclinical ALS study, and some surprising real and potential risks associated with this product.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/44870637</guid><pubDate>Tue, 08 Jun 2021 15:00:25 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/44870637/create_podcast_43.mp3" length="38114480" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Spirulina, or blue green algae, is a supplement that is claimed to have antioxidant and anti-inflammatory properties.  Here we review the problems we found with the single relevant preclinical ALS study, and some surprising real and potential risks...</itunes:subtitle><itunes:summary><![CDATA[Spirulina, or blue green algae, is a supplement that is claimed to have antioxidant and anti-inflammatory properties.  Here we review the problems we found with the single relevant preclinical ALS study, and some surprising real and potential risks associated with this product.]]></itunes:summary><itunes:duration>953</itunes:duration><itunes:keywords>algae,als,caregiver,health,mnd,neuroscience,patient,science,spirulina,supplement,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 42 - Lutimax</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-42-lutimax--44870610</link><description><![CDATA[Lutimax is a supplement containing Luteolin, a flavonoid that has antioxidant, anti-inflammatory and neuroprotective mechanisms.  Here we review case reports and a small trial claiming benefits in people with ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/44870610</guid><pubDate>Fri, 21 May 2021 19:24:53 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/44870610/create_podcast_42.mp3" length="33296420" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Lutimax is a supplement containing Luteolin, a flavonoid that has antioxidant, anti-inflammatory and neuroprotective mechanisms.  Here we review case reports and a small trial claiming benefits in people with ALS.</itunes:subtitle><itunes:summary><![CDATA[Lutimax is a supplement containing Luteolin, a flavonoid that has antioxidant, anti-inflammatory and neuroprotective mechanisms.  Here we review case reports and a small trial claiming benefits in people with ALS.]]></itunes:summary><itunes:duration>833</itunes:duration><itunes:keywords>als,health,lutimax,mnd,neurology,patient,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 41 - Bee Venom</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-41-bee-venom--44556150</link><description><![CDATA[Bee Venom contains substances that could plausibly affect the rate of ALS progression, and there are some positive (though flawed) preclinical studies and case reports associated with it. Since it has some potentially severe side effects and has not been tested in an ALS trial, our group advised against using it to try and slow ALS progression.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/44556150</guid><pubDate>Thu, 29 Apr 2021 16:58:40 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/44556150/create_podcast_41.mp3" length="30161288" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Bee Venom contains substances that could plausibly affect the rate of ALS progression, and there are some positive (though flawed) preclinical studies and case reports associated with it. Since it has some potentially severe side effects and has not...</itunes:subtitle><itunes:summary><![CDATA[Bee Venom contains substances that could plausibly affect the rate of ALS progression, and there are some positive (though flawed) preclinical studies and case reports associated with it. Since it has some potentially severe side effects and has not been tested in an ALS trial, our group advised against using it to try and slow ALS progression.]]></itunes:summary><itunes:duration>755</itunes:duration><itunes:keywords>als,bee,brain,caregiver,cure,health,medicine,mnd,neurology,patient,science,treatment,venom</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 40 - Vinpocetine</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-40-vinpocetine--42828991</link><description><![CDATA[Vinpocetine is a prescription drug in many countries and is used to treat patients with stroke and memory loss (though meta-analyses have questioned its benefit in these populations).  In the USA, it is sold as a nutritional supplement.  Here we review the potential mechanisms, data from pre-clinical models, case reports, and a trial, and the safety of vinpocetine as an ALS treatment.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/42828991</guid><pubDate>Mon, 25 Jan 2021 13:58:51 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/42828991/create_podcast_40.mp3" length="37560116" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Vinpocetine is a prescription drug in many countries and is used to treat patients with stroke and memory loss (though meta-analyses have questioned its benefit in these populations).  In the USA, it is sold as a nutritional supplement.  Here we...</itunes:subtitle><itunes:summary><![CDATA[Vinpocetine is a prescription drug in many countries and is used to treat patients with stroke and memory loss (though meta-analyses have questioned its benefit in these populations).  In the USA, it is sold as a nutritional supplement.  Here we review the potential mechanisms, data from pre-clinical models, case reports, and a trial, and the safety of vinpocetine as an ALS treatment.]]></itunes:summary><itunes:duration>939</itunes:duration><itunes:keywords>als,brain,caregiver,health,mnd,neurology,patient,science,treatment,vinpocetine</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 39 - Apoaequorin (Prevagen)</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-39-apoaequorin-prevagen--42828989</link><description><![CDATA[Apoaequorin (also called Prevagen) is a calcium binding protein first isolated from jellyfish.  Here we review the theory and the single trial of this compound for treating ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/42828989</guid><pubDate>Thu, 07 Jan 2021 16:10:11 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/42828989/create_podcast_39.mp3" length="27314300" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Apoaequorin (also called Prevagen) is a calcium binding protein first isolated from jellyfish.  Here we review the theory and the single trial of this compound for treating ALS.</itunes:subtitle><itunes:summary><![CDATA[Apoaequorin (also called Prevagen) is a calcium binding protein first isolated from jellyfish.  Here we review the theory and the single trial of this compound for treating ALS.]]></itunes:summary><itunes:duration>683</itunes:duration><itunes:keywords>als,apoaequorin,brain,caregiver,health,mnd,neurology,patient,prevagen,science,therapy,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 38 - Azathioprine</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-38-azathioprine--42540369</link><description><![CDATA[Azathioprine is an immunosuppressant drug.  Here we review the mechanisms by which it could slow ALS progression, discuss the ALS reversals and the negative ALS trials associated with this drug, and highlight some of the serious side effects that can occur in patients taking it.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/42540369</guid><pubDate>Thu, 17 Dec 2020 18:54:22 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/42540369/create_podcast_38.mp3" length="38073764" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Azathioprine is an immunosuppressant drug.  Here we review the mechanisms by which it could slow ALS progression, discuss the ALS reversals and the negative ALS trials associated with this drug, and highlight some of the serious side effects that can...</itunes:subtitle><itunes:summary><![CDATA[Azathioprine is an immunosuppressant drug.  Here we review the mechanisms by which it could slow ALS progression, discuss the ALS reversals and the negative ALS trials associated with this drug, and highlight some of the serious side effects that can occur in patients taking it.]]></itunes:summary><itunes:duration>952</itunes:duration><itunes:keywords>als,azathioprine,brain,caregiver,disease,health,mnd,neurology,patient,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 37 - Accilion</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-37-accilion--42243575</link><description><![CDATA[Accilion is a topical mineral cream.  Here we discuss why we do not think it has a plausible mechanism of action for treating ALS.  We also point out the problems interpreting the one anecdotal report of improvement in ALS symptoms associated with this treatment.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/42243575</guid><pubDate>Mon, 30 Nov 2020 18:29:02 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/42243575/create_podcast_37.mp3" length="30321020" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Accilion is a topical mineral cream.  Here we discuss why we do not think it has a plausible mechanism of action for treating ALS.  We also point out the problems interpreting the one anecdotal report of improvement in ALS symptoms associated with...</itunes:subtitle><itunes:summary><![CDATA[Accilion is a topical mineral cream.  Here we discuss why we do not think it has a plausible mechanism of action for treating ALS.  We also point out the problems interpreting the one anecdotal report of improvement in ALS symptoms associated with this treatment.]]></itunes:summary><itunes:duration>759</itunes:duration><itunes:keywords>accilion,als,caregiver,disease,health,mnd,neurology,patient,science,treament</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 36 - Vitamin E</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-36-vitamin-e--40958050</link><description><![CDATA[Vitamin E is one of the most popular, and most thoroughly studied, supplements in patients with ALS.  Although it is inexpensive and safe, well designed trials have failed to find evidence that it can slow, stop, or reverse ALS progression.  Interestingly, some data suggest that long term use of vitamin E might decrease a person's risk of getting ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/40958050</guid><pubDate>Mon, 05 Oct 2020 14:13:27 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/40958050/create_podcast_36.mp3" length="42784292" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Vitamin E is one of the most popular, and most thoroughly studied, supplements in patients with ALS.  Although it is inexpensive and safe, well designed trials have failed to find evidence that it can slow, stop, or reverse ALS progression....</itunes:subtitle><itunes:summary><![CDATA[Vitamin E is one of the most popular, and most thoroughly studied, supplements in patients with ALS.  Although it is inexpensive and safe, well designed trials have failed to find evidence that it can slow, stop, or reverse ALS progression.  Interestingly, some data suggest that long term use of vitamin E might decrease a person's risk of getting ALS.]]></itunes:summary><itunes:duration>1070</itunes:duration><itunes:keywords>als,caregiver,disease,health,mnd,patient,science,supplement,treatment,vitamin</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 35 - Leap2Bfit</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-35-leap2bfit--40958046</link><description><![CDATA[Leap2Bfit is a combination of many ingredients.  The exact amount of each ingredient is not clear.  While some of these products have plausible mechanisms and preclinical studies supporting their use in ALS, others do not.  There are 3 "ALS reversals" associated with this product, but these may have different explanations.  Several other patients under the care of ALSUntangled investigators have derived no clear benefit from this product.  There can be serious risks associated with some of the ingredients in this product.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/40958046</guid><pubDate>Thu, 17 Sep 2020 17:37:16 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/40958046/create_podcast_35.mp3" length="28092080" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Leap2Bfit is a combination of many ingredients.  The exact amount of each ingredient is not clear.  While some of these products have plausible mechanisms and preclinical studies supporting their use in ALS, others do not.  There are 3 "ALS reversals"...</itunes:subtitle><itunes:summary><![CDATA[Leap2Bfit is a combination of many ingredients.  The exact amount of each ingredient is not clear.  While some of these products have plausible mechanisms and preclinical studies supporting their use in ALS, others do not.  There are 3 "ALS reversals" associated with this product, but these may have different explanations.  Several other patients under the care of ALSUntangled investigators have derived no clear benefit from this product.  There can be serious risks associated with some of the ingredients in this product.]]></itunes:summary><itunes:duration>703</itunes:duration><itunes:keywords>als,caregiver,disease,health,leap2bfit,medicine,mnd,neurology,patient,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 34 - Ursodiol</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-34-ursodiol--40449299</link><description><![CDATA[Ursodiol or ursodeoxycholic acid (UDCA) is a bile acid derivative of cholesterol.  Since it can have antioxidant, anti-inflammatory and anti-apoptotic effects, it has mechanisms by which it could slow ALS progression.  Here we discuss trials of UDCA in PALS, including the taurine-conjugated form (TUDCA).  Some of these trials came out after our ALSUntangled review, and have changed our opinion about UDCA as an ALS treatment.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/40449299</guid><pubDate>Sat, 22 Aug 2020 13:42:14 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/40449299/create_podcast_34.mp3" length="33675392" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Ursodiol or ursodeoxycholic acid (UDCA) is a bile acid derivative of cholesterol.  Since it can have antioxidant, anti-inflammatory and anti-apoptotic effects, it has mechanisms by which it could slow ALS progression.  Here we discuss trials of UDCA...</itunes:subtitle><itunes:summary><![CDATA[Ursodiol or ursodeoxycholic acid (UDCA) is a bile acid derivative of cholesterol.  Since it can have antioxidant, anti-inflammatory and anti-apoptotic effects, it has mechanisms by which it could slow ALS progression.  Here we discuss trials of UDCA in PALS, including the taurine-conjugated form (TUDCA).  Some of these trials came out after our ALSUntangled review, and have changed our opinion about UDCA as an ALS treatment.]]></itunes:summary><itunes:duration>842</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,science,treatment,ursodiol</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 33 - Propofol</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-33-propofol--40126117</link><description><![CDATA[Propofol is an intravenous drug used for general anesthesia.  Some people with ALS have reported benefits from this drug.  Here we explore the rationale, the cases we found objective data on, and the serious risks of propofol as an ALS treatment.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/40126117</guid><pubDate>Mon, 03 Aug 2020 15:49:12 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/40126117/create_podcast_33.mp3" length="27388424" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Propofol is an intravenous drug used for general anesthesia.  Some people with ALS have reported benefits from this drug.  Here we explore the rationale, the cases we found objective data on, and the serious risks of propofol as an ALS treatment.</itunes:subtitle><itunes:summary><![CDATA[Propofol is an intravenous drug used for general anesthesia.  Some people with ALS have reported benefits from this drug.  Here we explore the rationale, the cases we found objective data on, and the serious risks of propofol as an ALS treatment.]]></itunes:summary><itunes:duration>685</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,propofol,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 32 - L-Carnitine</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-32-l-carnitine--38457947</link><description><![CDATA[Carnitines are inexpensive, generally safe forms of amino acids.  There are several mechanisms by which different carnitines might theoretically be helpful to a person with ALS.  A flawed Italian trial suggested that acetyl-L-carnitine could slow ALS progression.  Here we examine carnitines in more detail in hopes of helping patients with ALS make more informed decisions about them.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/38457947</guid><pubDate>Fri, 10 Jul 2020 21:32:53 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/38457947/create_podcast_32.mp3" length="41303900" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Carnitines are inexpensive, generally safe forms of amino acids.  There are several mechanisms by which different carnitines might theoretically be helpful to a person with ALS.  A flawed Italian trial suggested that acetyl-L-carnitine could slow ALS...</itunes:subtitle><itunes:summary><![CDATA[Carnitines are inexpensive, generally safe forms of amino acids.  There are several mechanisms by which different carnitines might theoretically be helpful to a person with ALS.  A flawed Italian trial suggested that acetyl-L-carnitine could slow ALS progression.  Here we examine carnitines in more detail in hopes of helping patients with ALS make more informed decisions about them.]]></itunes:summary><itunes:duration>1033</itunes:duration><itunes:keywords>als,aminoacid,caregiver,carnitine,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 31 – Gluten-free diet</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-31-gluten-free-diet--28846946</link><description><![CDATA[Gluten is a protein found in breads and cereals.  In a small percentage of people, ingestion of gluten can trigger an autoimmune disease.  Here we review the evidence that gluten-induced autoimmunity can mimic ALS, as well as the pros and cons of a gluten-free diet for people with ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/28846946</guid><pubDate>Thu, 04 Jun 2020 03:53:57 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/28846946/create_podcast_31.mp3" length="16844024" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Gluten is a protein found in breads and cereals.  In a small percentage of people, ingestion of gluten can trigger an autoimmune disease.  Here we review the evidence that gluten-induced autoimmunity can mimic ALS, as well as the pros and cons of a...</itunes:subtitle><itunes:summary><![CDATA[Gluten is a protein found in breads and cereals.  In a small percentage of people, ingestion of gluten can trigger an autoimmune disease.  Here we review the evidence that gluten-induced autoimmunity can mimic ALS, as well as the pros and cons of a gluten-free diet for people with ALS.]]></itunes:summary><itunes:duration>422</itunes:duration><itunes:keywords>als,caregiver,diet,gluten,health,medicine,mnd,neurology,patient,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 30 – Mito Q</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-30-mito-q--28464380</link><description><![CDATA[It is clear that oxidative stress is occurring in the brains and spinal cords of patients with ALS.  The mitochondria are a major source and target of this oxidative stress.  Here we describe an antioxidant that specifically targets mitochondria called MitoQ.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/28464380</guid><pubDate>Wed, 27 May 2020 19:44:27 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/28464380/create_podcast_30.mp3" length="25138604" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>It is clear that oxidative stress is occurring in the brains and spinal cords of patients with ALS.  The mitochondria are a major source and target of this oxidative stress.  Here we describe an antioxidant that specifically targets mitochondria...</itunes:subtitle><itunes:summary><![CDATA[It is clear that oxidative stress is occurring in the brains and spinal cords of patients with ALS.  The mitochondria are a major source and target of this oxidative stress.  Here we describe an antioxidant that specifically targets mitochondria called MitoQ.]]></itunes:summary><itunes:duration>629</itunes:duration><itunes:keywords>als,caregiver,disease,health,medicine,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 29 – Fecal Transplants</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-29-fecal-transplants--28464375</link><description><![CDATA[There is increasing evidence that the microbiome (the family of organisms that live in our guts) may play a role in driving ALS progression.  Here we review the evidence behind that idea, and explore fecal transplants as one potential way to alter the microbiome.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/28464375</guid><pubDate>Wed, 27 May 2020 19:44:18 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/28464375/create_podcast_29.mp3" length="33601268" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>There is increasing evidence that the microbiome (the family of organisms that live in our guts) may play a role in driving ALS progression.  Here we review the evidence behind that idea, and explore fecal transplants as one potential way to alter the...</itunes:subtitle><itunes:summary><![CDATA[There is increasing evidence that the microbiome (the family of organisms that live in our guts) may play a role in driving ALS progression.  Here we review the evidence behind that idea, and explore fecal transplants as one potential way to alter the microbiome.]]></itunes:summary><itunes:duration>841</itunes:duration><itunes:keywords>als,caregiver,disease,health,medicine,mnd,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 28 - List of rotten eggs</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-28-list-of-rotten-eggs--28464356</link><description><![CDATA[This is a list of a dozen things to watch out for when considering an alternative or off label treatment being advertised on the Internet.  These things tend to be associated with some of the less promising treatments that ALSUntangled has reviewed over the past 11 years.  The more of these things one finds associated with a product, the more wary we think they should be about it.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/28464356</guid><pubDate>Wed, 27 May 2020 19:44:05 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/28464356/create_podcast_28_ver2.mp3" length="49692440" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>This is a list of a dozen things to watch out for when considering an alternative or off label treatment being advertised on the Internet.  These things tend to be associated with some of the less promising treatments that ALSUntangled has reviewed...</itunes:subtitle><itunes:summary><![CDATA[This is a list of a dozen things to watch out for when considering an alternative or off label treatment being advertised on the Internet.  These things tend to be associated with some of the less promising treatments that ALSUntangled has reviewed over the past 11 years.  The more of these things one finds associated with a product, the more wary we think they should be about it.]]></itunes:summary><itunes:duration>1244</itunes:duration><itunes:keywords>als,caregiver,disease,health,medicine,mnd,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 27-Glutathione</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-27-glutathione--23291245</link><description><![CDATA[Glutathione is one of the major antioxidants in all our cells.  It is also one of the most popular supplements taken by patients with ALS around the world.  Here we review what we learned about the mechanisms of action, pre-clinical data, case reports, trials and risks of taking glutathione for ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/23291245</guid><pubDate>Fri, 28 Feb 2020 16:22:45 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/23291245/create_podcast_27.mp3" length="27403040" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Glutathione is one of the major antioxidants in all our cells.  It is also one of the most popular supplements taken by patients with ALS around the world.  Here we review what we learned about the mechanisms of action, pre-clinical data, case...</itunes:subtitle><itunes:summary><![CDATA[Glutathione is one of the major antioxidants in all our cells.  It is also one of the most popular supplements taken by patients with ALS around the world.  Here we review what we learned about the mechanisms of action, pre-clinical data, case reports, trials and risks of taking glutathione for ALS.]]></itunes:summary><itunes:duration>686</itunes:duration><itunes:keywords>als,caregiver,disease,health,medicine,mnd,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 26 - Vitamin D</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-26-vitamin-d--22518184</link><description><![CDATA[Many patients with ALS have low vitamin D levels.  Here we discuss ways that vitamin D might be important in slowing ALS progression, and in reducing the risk of bone fractures from falls.  We explain why we think it is important for patients with ALS to have their vitamin D levels checked, and if these levels are low, to get them into the normal range.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/22518184</guid><pubDate>Fri, 07 Feb 2020 15:41:40 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/22518184/create_podcast_26.mp3" length="23044340" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Many patients with ALS have low vitamin D levels.  Here we discuss ways that vitamin D might be important in slowing ALS progression, and in reducing the risk of bone fractures from falls.  We explain why we think it is important for patients with ALS...</itunes:subtitle><itunes:summary><![CDATA[Many patients with ALS have low vitamin D levels.  Here we discuss ways that vitamin D might be important in slowing ALS progression, and in reducing the risk of bone fractures from falls.  We explain why we think it is important for patients with ALS to have their vitamin D levels checked, and if these levels are low, to get them into the normal range.]]></itunes:summary><itunes:duration>577</itunes:duration><itunes:keywords>als,caregiver,disease,health,mnd,neurology,patient,research,science,treatment,vitamin</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 25 - Rife Machine and Retroviruses</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-25-rife-machine-and-retroviruses--22478155</link><description><![CDATA[In the 1930s, Royal Raymond Rife developed special microscopes he claimed he could visualize living microorganisms, including viruses too small to be seen with any other existing technology, via the color of auras emitted as they vibrated.  He also claimed to have developed a machine that used radio waves to kill these organisms.  While the use of radio waves to treat disease (a field called "radionics") has been debunked by scientists, it turns out that tiny organisms called retroviruses may actually play a role in causing some cases of ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/22478155</guid><pubDate>Fri, 07 Feb 2020 15:41:35 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/22478155/create_podcast_25.mp3" length="19696232" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>In the 1930s, Royal Raymond Rife developed special microscopes he claimed he could visualize living microorganisms, including viruses too small to be seen with any other existing technology, via the color of auras emitted as they vibrated.  He also...</itunes:subtitle><itunes:summary><![CDATA[In the 1930s, Royal Raymond Rife developed special microscopes he claimed he could visualize living microorganisms, including viruses too small to be seen with any other existing technology, via the color of auras emitted as they vibrated.  He also claimed to have developed a machine that used radio waves to kill these organisms.  While the use of radio waves to treat disease (a field called "radionics") has been debunked by scientists, it turns out that tiny organisms called retroviruses may actually play a role in causing some cases of ALS.]]></itunes:summary><itunes:duration>493</itunes:duration><itunes:keywords>als,caregiver,disease,health,medicine,mnd,neurology,patient,research,retrovirus,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 24 - “When ALS is Lyme”</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-24-when-als-is-lyme--19990098</link><description><![CDATA[Here we review an online manuscript called “When ALS is Lyme.”  As in our previous ALSUntangled review, our large international team of clinicians and scientists again finds no convincing scientific evidence for a connection between Lyme disease and ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/19990098</guid><pubDate>Wed, 13 Nov 2019 16:28:13 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/19990098/create_podcast_24.mp3" length="30497456" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Here we review an online manuscript called “When ALS is Lyme.”  As in our previous ALSUntangled review, our large international team of clinicians and scientists again finds no convincing scientific evidence for a connection between Lyme disease and ALS.</itunes:subtitle><itunes:summary><![CDATA[Here we review an online manuscript called “When ALS is Lyme.”  As in our previous ALSUntangled review, our large international team of clinicians and scientists again finds no convincing scientific evidence for a connection between Lyme disease and ALS.]]></itunes:summary><itunes:duration>763</itunes:duration><itunes:keywords>als,caregiver,disease,health,lyme,medicine,mnd,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 23 - Hyperbaric Oxygen</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-23-hyperbaric-oxygen--19990095</link><description><![CDATA[Hyperbaric oxygen can increase heat shock proteins, which might be useful in decreasing oxidative stress and protein aggregation in ALS.  It looked promising in animal models of ALS, and is associated with 1 validated case of “ALS reversal.”  Unfortunately a clinical trial in patients with ALS showed no benefit and this can cause serious side effects.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/19990095</guid><pubDate>Wed, 13 Nov 2019 16:28:10 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/19990095/create_podcast_23.mp3" length="35500304" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Hyperbaric oxygen can increase heat shock proteins, which might be useful in decreasing oxidative stress and protein aggregation in ALS.  It looked promising in animal models of ALS, and is associated with 1 validated case of “ALS reversal.”...</itunes:subtitle><itunes:summary><![CDATA[Hyperbaric oxygen can increase heat shock proteins, which might be useful in decreasing oxidative stress and protein aggregation in ALS.  It looked promising in animal models of ALS, and is associated with 1 validated case of “ALS reversal.”  Unfortunately a clinical trial in patients with ALS showed no benefit and this can cause serious side effects.]]></itunes:summary><itunes:duration>888</itunes:duration><itunes:keywords>als,caregiver,health,hyperbaric,medicine,mnd,neurology,oxygen,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 22 - Ayahuasca</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-22-ayahuasca--19990092</link><description><![CDATA[Ayahuasca is a hallucinogen used in religious rituals in the Amazon.  This podcast reviews the potential mechanisms by which it might slow the progression of ALS, as well as a few case reports suggesting benefit.  Unfortunately we learned this product can cause death and/or hospitalization.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/19990092</guid><pubDate>Wed, 13 Nov 2019 16:28:05 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/19990092/create_podcasts_22.mp3" length="26283872" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Ayahuasca is a hallucinogen used in religious rituals in the Amazon.  This podcast reviews the potential mechanisms by which it might slow the progression of ALS, as well as a few case reports suggesting benefit.  Unfortunately we learned this product...</itunes:subtitle><itunes:summary><![CDATA[Ayahuasca is a hallucinogen used in religious rituals in the Amazon.  This podcast reviews the potential mechanisms by which it might slow the progression of ALS, as well as a few case reports suggesting benefit.  Unfortunately we learned this product can cause death and/or hospitalization.]]></itunes:summary><itunes:duration>658</itunes:duration><itunes:keywords>als,ayahuasca,caregiver,health,medicine,mnd,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 21 - Anti-fungals</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-21-anti-fungals--19990085</link><description><![CDATA[One group has reported evidence of fungal infections in the brains of patients who died from ALS.  Here we explore the potential explanations for this finding, and the potential for anti-fungal medications as an ALS treatment.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/19990085</guid><pubDate>Wed, 13 Nov 2019 16:28:01 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/19990085/create_podcasts_21.mp3" length="22430468" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>One group has reported evidence of fungal infections in the brains of patients who died from ALS.  Here we explore the potential explanations for this finding, and the potential for anti-fungal medications as an ALS treatment.</itunes:subtitle><itunes:summary><![CDATA[One group has reported evidence of fungal infections in the brains of patients who died from ALS.  Here we explore the potential explanations for this finding, and the potential for anti-fungal medications as an ALS treatment.]]></itunes:summary><itunes:duration>561</itunes:duration><itunes:keywords>als,antifungal,caregiver,health,medicine,mnd,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 20 – Resveratrol</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-20-resveratrol--18572961</link><description><![CDATA[Resveratrol is a naturally occurring chemical found in grapes, berries and peanuts. By modulating sirtuins, protein aggregation and the gut microbiome, it could theoretically slow ALS progression.  We describe an animal study and an "ALS Reversal" that provide some support for this idea.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/18572961</guid><pubDate>Wed, 17 Jul 2019 16:19:43 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/18572961/create_podcast_20_ver3.mp3" length="36430508" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Resveratrol is a naturally occurring chemical found in grapes, berries and peanuts. By modulating sirtuins, protein aggregation and the gut microbiome, it could theoretically slow ALS progression.  We describe an animal study and an "ALS Reversal"...</itunes:subtitle><itunes:summary><![CDATA[Resveratrol is a naturally occurring chemical found in grapes, berries and peanuts. By modulating sirtuins, protein aggregation and the gut microbiome, it could theoretically slow ALS progression.  We describe an animal study and an "ALS Reversal" that provide some support for this idea.]]></itunes:summary><itunes:duration>911</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,research,resveratrol,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 19 – RT001</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-19-rt001--18572950</link><description><![CDATA[Oxidative stress is widely believed to be one of the molecular pathways driving ALS progression.  Many different antioxidants have been tried in people with ALS, with little or no previous benefit.  RT001 fights oxidative stress in a unique way.  Here we show why this might be more effective than other antioxidants and review some very early data from the RT001 expanded access program.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/18572950</guid><pubDate>Wed, 17 Jul 2019 16:19:40 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/18572950/create_podcast_19_ver3.mp3" length="32981132" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Oxidative stress is widely believed to be one of the molecular pathways driving ALS progression.  Many different antioxidants have been tried in people with ALS, with little or no previous benefit.  RT001 fights oxidative stress in a unique way.  Here...</itunes:subtitle><itunes:summary><![CDATA[Oxidative stress is widely believed to be one of the molecular pathways driving ALS progression.  Many different antioxidants have been tried in people with ALS, with little or no previous benefit.  RT001 fights oxidative stress in a unique way.  Here we show why this might be more effective than other antioxidants and review some very early data from the RT001 expanded access program.]]></itunes:summary><itunes:duration>825</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,research,rt001,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 18 – Penicillin G/Hydrocortisone</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-18-penicillin-g-hydrocortisone--18572934</link><description><![CDATA[Penicillin G is an antibiotic and hydrocortisone is an anti-inflammatory.  These 2 drugs have been successfully used in combination to treat cases of syphilis mimicking ALS.  Here we show 1 person's theory on why they could help people with ALS who do not have syphilis, and critique some of his case reports.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/18572934</guid><pubDate>Wed, 17 Jul 2019 16:19:36 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/18572934/create_podcast_18_ver3.mp3" length="31570688" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Penicillin G is an antibiotic and hydrocortisone is an anti-inflammatory.  These 2 drugs have been successfully used in combination to treat cases of syphilis mimicking ALS.  Here we show 1 person's theory on why they could help people with ALS who do...</itunes:subtitle><itunes:summary><![CDATA[Penicillin G is an antibiotic and hydrocortisone is an anti-inflammatory.  These 2 drugs have been successfully used in combination to treat cases of syphilis mimicking ALS.  Here we show 1 person's theory on why they could help people with ALS who do not have syphilis, and critique some of his case reports.]]></itunes:summary><itunes:duration>790</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 17 – Perampanel</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-17-perampanel--18572909</link><description><![CDATA[Perampanel (also called Fycompa) is a drug used to treat epileptic seizures.  Here we review the reasons it might be useful in slowing ALS progression and describe what happened when ALS mice and a small number of people with ALS were treated with this and similar drugs.  We describe the ongoing ALS trials and review safety and dosing considerations.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/18572909</guid><pubDate>Wed, 17 Jul 2019 16:19:31 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/18572909/create_podcast_17_ver2.mp3" length="40059452" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Perampanel (also called Fycompa) is a drug used to treat epileptic seizures.  Here we review the reasons it might be useful in slowing ALS progression and describe what happened when ALS mice and a small number of people with ALS were treated with...</itunes:subtitle><itunes:summary><![CDATA[Perampanel (also called Fycompa) is a drug used to treat epileptic seizures.  Here we review the reasons it might be useful in slowing ALS progression and describe what happened when ALS mice and a small number of people with ALS were treated with this and similar drugs.  We describe the ongoing ALS trials and review safety and dosing considerations.]]></itunes:summary><itunes:duration>1002</itunes:duration><itunes:keywords>als,caregiver,drug,health,medicine,mnd,neurology,patient,perampanel,research,science,seizure,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 16 – Acupuncture</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-16-acupuncture--16530061</link><description><![CDATA[Acupuncture is often thought of as a treatment option for pain.  In this podcast we look critically at whether acupuncture might have mechanisms that could slow ALS progression, and we review published trials of acupuncture in patients with ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/16530061</guid><pubDate>Thu, 20 Dec 2018 12:51:46 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/16530061/create_podcast_16.mp3" length="27776792" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Acupuncture is often thought of as a treatment option for pain.  In this podcast we look critically at whether acupuncture might have mechanisms that could slow ALS progression, and we review published trials of acupuncture in patients with ALS.</itunes:subtitle><itunes:summary><![CDATA[Acupuncture is often thought of as a treatment option for pain.  In this podcast we look critically at whether acupuncture might have mechanisms that could slow ALS progression, and we review published trials of acupuncture in patients with ALS.]]></itunes:summary><itunes:duration>695</itunes:duration><itunes:keywords>acupuncture,als,caregiver,health,medicine,mnd,neurology,patients,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 15 – Low dose naltrexone for ALS</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-15-low-dose-naltrexone-for-als--16530060</link><description><![CDATA[Low dose naltrexone (LDN) has been proposed as a treatment for a long list of different diseases.  Here we examine the potential mechanisms, pre-clinical data and anecdotal reports on LDN in ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/16530060</guid><pubDate>Thu, 20 Dec 2018 12:51:43 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/16530060/create_podcast_15.mp3" length="14680856" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Low dose naltrexone (LDN) has been proposed as a treatment for a long list of different diseases.  Here we examine the potential mechanisms, pre-clinical data and anecdotal reports on LDN in ALS.</itunes:subtitle><itunes:summary><![CDATA[Low dose naltrexone (LDN) has been proposed as a treatment for a long list of different diseases.  Here we examine the potential mechanisms, pre-clinical data and anecdotal reports on LDN in ALS.]]></itunes:summary><itunes:duration>368</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patients,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 14 – Cannabis</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-14-cannabis--16530059</link><description><![CDATA[Many patients over the years have told us that forms of cannabis can help bothersome ALS symptoms such as pain, cramps, fasciculations, and low appetite.  Here we review theoretical, pre-clinical and anecdotal evidence that forms of cannabis might slow the progression of ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/16530059</guid><pubDate>Thu, 20 Dec 2018 12:51:38 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/16530059/create_podcast_14.mp3" length="37590392" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Many patients over the years have told us that forms of cannabis can help bothersome ALS symptoms such as pain, cramps, fasciculations, and low appetite.  Here we review theoretical, pre-clinical and anecdotal evidence that forms of cannabis might...</itunes:subtitle><itunes:summary><![CDATA[Many patients over the years have told us that forms of cannabis can help bothersome ALS symptoms such as pain, cramps, fasciculations, and low appetite.  Here we review theoretical, pre-clinical and anecdotal evidence that forms of cannabis might slow the progression of ALS.]]></itunes:summary><itunes:duration>940</itunes:duration><itunes:keywords>als,cannabis,caregiver,health,medicine,mnd,neurology,patients,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALS Untangled Series: Ep. 13 – Antiretrovirals</title><link>https://www.spreaker.com/episode/als-untangled-series-ep-13-antiretrovirals--16530058</link><description><![CDATA[Several observations suggest that retroviruses might be able to kill motor neurons, causing forms of ALS.  Here we review these data, focusing on the theory that reactivation of an "endogenous" retrovirus we all have hiding in our genes called Herv-K might cause some cases of sporadic ALS.  We examine drugs that attack retroviruses as potential treatments for patients with ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/16530058</guid><pubDate>Thu, 20 Dec 2018 12:51:32 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/16530058/create_podcast_13.mp3" length="35737292" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Several observations suggest that retroviruses might be able to kill motor neurons, causing forms of ALS.  Here we review these data, focusing on the theory that reactivation of an "endogenous" retrovirus we all have hiding in our genes called Herv-K...</itunes:subtitle><itunes:summary><![CDATA[Several observations suggest that retroviruses might be able to kill motor neurons, causing forms of ALS.  Here we review these data, focusing on the theory that reactivation of an "endogenous" retrovirus we all have hiding in our genes called Herv-K might cause some cases of sporadic ALS.  We examine drugs that attack retroviruses as potential treatments for patients with ALS.]]></itunes:summary><itunes:duration>894</itunes:duration><itunes:keywords>als,antiretrovirals,caregiver,health,medicine,mnd,neurology,patients,research,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 12 - Deanna Protocol</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-12-deanna-protocol--15027788</link><description><![CDATA[With more than 30,000 downloads, this remains our most popular ALSUntangled review of all time. Here we review the history and evolution of this cocktail, including what has been learned about it since we published our review.  We highlight the problems with interpreting unverified anecdotal data in ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/15027788</guid><pubDate>Tue, 12 Jun 2018 14:39:32 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/15027788/create_podcast_12.mp3" length="37480772" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>With more than 30,000 downloads, this remains our most popular ALSUntangled review of all time. Here we review the history and evolution of this cocktail, including what has been learned about it since we published our review.  We highlight the...</itunes:subtitle><itunes:summary><![CDATA[With more than 30,000 downloads, this remains our most popular ALSUntangled review of all time. Here we review the history and evolution of this cocktail, including what has been learned about it since we published our review.  We highlight the problems with interpreting unverified anecdotal data in ALS.]]></itunes:summary><itunes:duration>938</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 11 - Protandim</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-11-protandim--15027786</link><description><![CDATA[Protandim is an oral tablet derived from 5 different plants, which may be able to activate an antioxidant pathway in cells.  This treatment is also associated with an “ALS reversal,” appears reasonably safe and inexpensive, and warrants further study in people with ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/15027786</guid><pubDate>Tue, 12 Jun 2018 14:38:34 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/15027786/create_podcast_11.mp3" length="16621652" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Protandim is an oral tablet derived from 5 different plants, which may be able to activate an antioxidant pathway in cells.  This treatment is also associated with an “ALS reversal,” appears reasonably safe and inexpensive, and warrants further study...</itunes:subtitle><itunes:summary><![CDATA[Protandim is an oral tablet derived from 5 different plants, which may be able to activate an antioxidant pathway in cells.  This treatment is also associated with an “ALS reversal,” appears reasonably safe and inexpensive, and warrants further study in people with ALS.]]></itunes:summary><itunes:duration>416</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 10 - Lunasin</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-10-lunasin--15027777</link><description><![CDATA[Lunasin, a peptide first isolated from soybeans, is associated with an “ALS reversal.” We explain why we once had great hope for this as an ALS treatment.  We then review the results from a recently-completed, year-long clinical trial of Lunasin in 50 people with ALS.  Unfortunately, no one in this trial had an ALS reversal or even any detectable slowing of their progression, and there were unexpected GI side effects including constipation severe enough to warrant hospitalization.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/15027777</guid><pubDate>Tue, 12 Jun 2018 14:37:48 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/15027777/create_podcast_10.mp3" length="43009796" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Lunasin, a peptide first isolated from soybeans, is associated with an “ALS reversal.” We explain why we once had great hope for this as an ALS treatment.  We then review the results from a recently-completed, year-long clinical trial of Lunasin in 50...</itunes:subtitle><itunes:summary><![CDATA[Lunasin, a peptide first isolated from soybeans, is associated with an “ALS reversal.” We explain why we once had great hope for this as an ALS treatment.  We then review the results from a recently-completed, year-long clinical trial of Lunasin in 50 people with ALS.  Unfortunately, no one in this trial had an ALS reversal or even any detectable slowing of their progression, and there were unexpected GI side effects including constipation severe enough to warrant hospitalization.]]></itunes:summary><itunes:duration>1076</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 9 - Coconut Oil</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-9-coconut-oil--15027764</link><description><![CDATA[Once ingested, coconut oil gets converted to ketone bodies which might be able to help central nervous system cells produce more normal levels of energy, and be more resistant to ALS. Here we discuss the potential utility of coconut oil and other ways to elevate ketone bodies in the treatment of ALS, including an upcoming trial of Triheptanoin.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/15027764</guid><pubDate>Tue, 12 Jun 2018 14:37:03 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/15027764/create_podcast_9.mp3" length="30826316" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Once ingested, coconut oil gets converted to ketone bodies which might be able to help central nervous system cells produce more normal levels of energy, and be more resistant to ALS. Here we discuss the potential utility of coconut oil and other ways...</itunes:subtitle><itunes:summary><![CDATA[Once ingested, coconut oil gets converted to ketone bodies which might be able to help central nervous system cells produce more normal levels of energy, and be more resistant to ALS. Here we discuss the potential utility of coconut oil and other ways to elevate ketone bodies in the treatment of ALS, including an upcoming trial of Triheptanoin.]]></itunes:summary><itunes:duration>771</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 8 - L-serine</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-8-l-serine--14524520</link><description><![CDATA[BMAA is a toxin that may cause some forms of sporadic ALS.  Here we discuss how L-serine, an inexpensive, widely available amino acid supplement, might block BMAA toxicity and thus be of use for preventing or slowing ALS progression.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14524520</guid><pubDate>Fri, 13 Apr 2018 17:38:57 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14524520/create_podcast_8.mp3" length="26885216" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>BMAA is a toxin that may cause some forms of sporadic ALS.  Here we discuss how L-serine, an inexpensive, widely available amino acid supplement, might block BMAA toxicity and thus be of use for preventing or slowing ALS progression.</itunes:subtitle><itunes:summary><![CDATA[BMAA is a toxin that may cause some forms of sporadic ALS.  Here we discuss how L-serine, an inexpensive, widely available amino acid supplement, might block BMAA toxicity and thus be of use for preventing or slowing ALS progression.]]></itunes:summary><itunes:duration>673</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,patients,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 7 - Acuscope</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-7-acuscope--14524507</link><description><![CDATA[Acuscope is a machine that delivers a very small amount of electric current to muscles.  In this podcast we report that acuscope treatment appears fairly safe, but is expensive and has shown no clear benefit in slowing ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14524507</guid><pubDate>Fri, 13 Apr 2018 17:38:53 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14524507/create_podcast_7.mp3" length="11744084" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Acuscope is a machine that delivers a very small amount of electric current to muscles.  In this podcast we report that acuscope treatment appears fairly safe, but is expensive and has shown no clear benefit in slowing ALS.</itunes:subtitle><itunes:summary><![CDATA[Acuscope is a machine that delivers a very small amount of electric current to muscles.  In this podcast we report that acuscope treatment appears fairly safe, but is expensive and has shown no clear benefit in slowing ALS.]]></itunes:summary><itunes:duration>294</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patient,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 6 - Curcumin</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-6-curcumin--14524492</link><description><![CDATA[Curcumin is an ingredient in the spice tumeric and in curry powder.  It has multiple plausible mechanisms by which it might slow ALS progression.  There are 3 people with validated ALS diagnoses who recovered significant lost motor function (ALS reversals) on forms of it.  Here we discuss the specific curcumin formulation and dosage that we think is promising enough to warrant further study in ALS.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14524492</guid><pubDate>Fri, 13 Apr 2018 17:38:43 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14524492/create_podcast_6.mp3" length="20550224" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Curcumin is an ingredient in the spice tumeric and in curry powder.  It has multiple plausible mechanisms by which it might slow ALS progression.  There are 3 people with validated ALS diagnoses who recovered significant lost motor function (ALS...</itunes:subtitle><itunes:summary><![CDATA[Curcumin is an ingredient in the spice tumeric and in curry powder.  It has multiple plausible mechanisms by which it might slow ALS progression.  There are 3 people with validated ALS diagnoses who recovered significant lost motor function (ALS reversals) on forms of it.  Here we discuss the specific curcumin formulation and dosage that we think is promising enough to warrant further study in ALS.]]></itunes:summary><itunes:duration>514</itunes:duration><itunes:keywords>als,caregiver,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 5 - Inosine</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-5-inosine--14524474</link><description><![CDATA[Inosine is a naturally occurring oral supplement that raises blood urate levels.  In this podcast, we discuss ways this might slow ALS progression and why it needs careful blood and urine monitoring]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14524474</guid><pubDate>Fri, 13 Apr 2018 17:38:35 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14524474/create_podcast_5_1.mp3" length="30347120" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Inosine is a naturally occurring oral supplement that raises blood urate levels.  In this podcast, we discuss ways this might slow ALS progression and why it needs careful blood and urine monitoring</itunes:subtitle><itunes:summary><![CDATA[Inosine is a naturally occurring oral supplement that raises blood urate levels.  In this podcast, we discuss ways this might slow ALS progression and why it needs careful blood and urine monitoring]]></itunes:summary><itunes:duration>759</itunes:duration><itunes:keywords>als,caregivers,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 4 - Copper</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-4-copper--14182813</link><description><![CDATA[CuATSM is a very promising ALS treatment that is in development.  Here we discuss copper metabolism in ALS, why this specific therapy might help and why less complicated copper supplements are unlikely to be of any benefit.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14182813</guid><pubDate>Wed, 07 Mar 2018 15:08:08 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14182813/create_podcast_4.mp3" length="33701492" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>CuATSM is a very promising ALS treatment that is in development.  Here we discuss copper metabolism in ALS, why this specific therapy might help and why less complicated copper supplements are unlikely to be of any benefit.</itunes:subtitle><itunes:summary><![CDATA[CuATSM is a very promising ALS treatment that is in development.  Here we discuss copper metabolism in ALS, why this specific therapy might help and why less complicated copper supplements are unlikely to be of any benefit.]]></itunes:summary><itunes:duration>843</itunes:duration><itunes:keywords>als,caregivers,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 3 - Elysium health’s “Basis” therapy</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-3-elysium-health-s-basis-therapy--14182810</link><description><![CDATA[Basis in an over the counter supplement containing nicotinamide ribose and pterostilbene.  In this podcast, we review the theories on how this might help a person with ALS, as well as the potential risks and costs involved.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14182810</guid><pubDate>Wed, 07 Mar 2018 15:08:01 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14182810/create_podcast_3.mp3" length="26978132" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>Basis in an over the counter supplement containing nicotinamide ribose and pterostilbene.  In this podcast, we review the theories on how this might help a person with ALS, as well as the potential risks and costs involved.</itunes:subtitle><itunes:summary><![CDATA[Basis in an over the counter supplement containing nicotinamide ribose and pterostilbene.  In this podcast, we review the theories on how this might help a person with ALS, as well as the potential risks and costs involved.]]></itunes:summary><itunes:duration>675</itunes:duration><itunes:keywords>als,caregivers,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 2 - Eric is Winning</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-2-eric-is-winning--14182808</link><description><![CDATA[In this podcast, we discuss one of the most requested ALSUntangled reviews of all time-a complicated treatment cocktail described in a book written by a patient with slowly progressive ALS called "Eric is Winning."]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14182808</guid><pubDate>Wed, 07 Mar 2018 15:07:55 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14182808/create_podcast_2.mp3" length="34218272" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>In this podcast, we discuss one of the most requested ALSUntangled reviews of all time-a complicated treatment cocktail described in a book written by a patient with slowly progressive ALS called "Eric is Winning."</itunes:subtitle><itunes:summary><![CDATA[In this podcast, we discuss one of the most requested ALSUntangled reviews of all time-a complicated treatment cocktail described in a book written by a patient with slowly progressive ALS called "Eric is Winning."]]></itunes:summary><itunes:duration>856</itunes:duration><itunes:keywords>als,caregivers,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>ALSUntangled Series: Ep. 1 - ALSUntangled untangled</title><link>https://www.spreaker.com/episode/alsuntangled-series-ep-1-alsuntangled-untangled--14182288</link><description><![CDATA[ALSUntangled is an internet based program that reviews alternative and off label treatments, with the goal of helping people with ALS make more informed decisions about them. This podcast describes how the program works.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/14182288</guid><pubDate>Wed, 07 Mar 2018 15:07:48 +0000</pubDate><enclosure url="https://api.spreaker.com/download/episode/14182288/create_podcast_1.mp3" length="25568732" type="audio/mpeg"/><itunes:author>CReATe Consortium</itunes:author><itunes:subtitle>ALSUntangled is an internet based program that reviews alternative and off label treatments, with the goal of helping people with ALS make more informed decisions about them. This podcast describes how the program works.</itunes:subtitle><itunes:summary><![CDATA[ALSUntangled is an internet based program that reviews alternative and off label treatments, with the goal of helping people with ALS make more informed decisions about them. This podcast describes how the program works.]]></itunes:summary><itunes:duration>640</itunes:duration><itunes:keywords>als,caregivers,health,medicine,mnd,neurology,patients,science,treatment</itunes:keywords><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg"/><itunes:episodeType>full</itunes:episodeType></item></channel></rss>
